Truist Financial Reaffirms “Buy” Rating for Kymera Therapeutics (NASDAQ:KYMR)

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “buy” rating reaffirmed by equities researchers at Truist Financial in a report released on Friday, Benzinga reports. They presently have a $150.00 target price on the stock, up from their previous target price of $136.00. Truist Financial‘s target price points to a potential upside of 24.07% from the stock’s current price.

Several other equities research analysts also recently issued reports on KYMR. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, October 15th. Deutsche Bank Aktiengesellschaft assumed coverage on Kymera Therapeutics in a report on Thursday, July 30th. They set a “hold” rating and a $120.00 price objective on the stock. Piper Sandler restated an “overweight” rating and issued a $140.00 target price on shares of Kymera Therapeutics in a research note on Wednesday, September 23rd. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday. Finally, Loop Capital set a $132.00 price target on shares of Kymera Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $137.92.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR traded down $1.70 during mid-day trading on Friday, reaching $120.90. 375,810 shares of the company’s stock were exchanged, compared to its average volume of 746,932. The firm has a market capitalization of $10.05 billion, a price-to-earnings ratio of -37.34 and a beta of 1.98. Kymera Therapeutics has a 52 week low of $55.66 and a 52 week high of $130.05. The firm has a 50-day moving average price of $114.83 and a two-hundred day moving average price of $96.08.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $3.28 million. During the same quarter in the previous year, the company posted ($0.94) EPS. Kymera Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis. As a group, sell-side analysts forecast that Kymera Therapeutics will post -3.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider directly owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. 15.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently bought and sold shares of KYMR. BlackRock Inc. purchased a new stake in shares of Kymera Therapeutics during the second quarter valued at approximately $635,067,000. Merck & Co. Inc. purchased a new stake in Kymera Therapeutics during the 2nd quarter valued at $88,544,161. Jennison Associates LLC boosted its position in Kymera Therapeutics by 2.5% during the 1st quarter. Jennison Associates LLC now owns 508,999 shares of the company’s stock valued at $42,395,000 after buying an additional 12,334 shares during the period. Bank of America Corp DE bought a new stake in Kymera Therapeutics in the 2nd quarter worth $43,378,000. Finally, Braidwell LP grew its holdings in Kymera Therapeutics by 12.0% in the 2nd quarter. Braidwell LP now owns 378,163 shares of the company’s stock worth $43,364,000 after acquiring an additional 40,604 shares during the last quarter.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, an oral IRF5 degrader. The drug produced deep, sustained IRF5 degradation, robust changes in disease-relevant biomarkers and a favorable safety profile in healthy volunteers, strengthening the case for continued development in immunological diseases. Kymera Announces Q3 2026 Results and KT-579 Phase 1 Data
• Positive Sentiment: Truist Securities raised its price target on KYMR to $150 from $136 while maintaining a Buy rating, signaling increased confidence in Kymera’s pipeline and potential upside. Truist Raises Kymera Price Target
• Positive Sentiment: BTIG Research also increased its target to $139 from $134 and initiated or maintained a Buy rating, adding further analyst support for the shares.
• Neutral Sentiment: The company’s Q3 earnings call focused on the financial results and KT-579 development update. Investors are likely to look for additional guidance on clinical timelines, future trials and cash resources as Kymera advances its pipeline. Kymera Q3 2026 Earnings Call Transcript
• Negative Sentiment: Kymera reported a third-quarter loss of $1.32 per share, wider than the $1.26 analyst consensus, while revenue of $1.35 million fell short of the $3.28 million estimate. The company’s negative profitability metrics and widening net loss remain risks for investors in this clinical-stage biotech. Kymera Q3 2026 Financial Results

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.